Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Colonic Neoplasms 1Carcinoma 1

Interventions

Oxaliplatin 14Cetuximab 11Leucovorin 9Fluorouracil 9Magnetic Resonance Spectroscopy 8Nivolumab 7pembrolizumab 6Capecitabine 6encorafenib 5Irinotecan 5Bevacizumab 5dehydroftorafur 4Specimen Handling 4adagrasib 3Immunoglobulin G 3Disulfides 3Biopsy 3selpercatinib 2durvalumab 2cemiplimab 2X-Rays 2Watchful Waiting 2Standard of Care 2Radiotherapy 2Panitumumab 2Observation 2Ipilimumab 2Injections 2Gemcitabine 2Folfox protocol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colonic Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡